UBS upgraded Cryoport (CYRX) to Buy from Neutral with a $10 price target UBS believes that scaling cell and gene therapy service offerings provide a credible pathway to low-double-digit-plus mid- to long-term sales growth and positive free cash flow, the analyst tells investors in a research note. Challenges like broader biopharma market weakness and headwinds in MVE are well understood, appear to be stabilizing, and provide an attractive entry point, the firm says.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CYRX:
- CryoPort’s Mixed Performance and Sector Uncertainties Justify Hold Rating
- CryoPort’s Stabilization Amid Market Uncertainties: A Hold Rating Analysis
- CryoPort’s Strong Performance and Strategic Positioning Earns Buy Rating from Analyst
- CryoPort Inc’s Earnings Call: Strong Growth and Optimism
- CryoPort trading resumes